IFNG and precursor B-cell acute lymphoblastic leukemia: To further improve the therapeutic efficacy of the strategy used in B-ALL, the preclinical use of Tie2-monocytes for the co-release of interferon gamma (IFNγ) and tumor necrosis factor alpha (TNFα) was tested in vivo [35].